Clinical Study to Evaluate The Cardioprotective Effect of Pentoxifylline Against Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients

This study is looking at whether a drug called pentoxifylline can protect the heart from damage caused by doxorubicin, a common chemotherapy drug used to treat breast cancer. Heart damage is a known side effect of doxorubicin, and this trial aims to see if pentoxifylline can reduce that risk. **You may be eligible if...** - You are 18 to 65 years old - You have been newly diagnosed with stage I, II, or III breast cancer (confirmed by biopsy) - You have not yet received any chemotherapy - You are planned to receive at least 4 cycles of doxorubicin - Your heart function (ejection fraction) is at or above normal (≥55%) on an echocardiogram - Your blood counts and organ function are within acceptable ranges **You may NOT be eligible if...** - You have a history of heart disease or a previous heart attack - You have stage IV (metastatic) breast cancer - You have significant liver or kidney problems - You are pregnant or breastfeeding - You have a known allergy to pentoxifylline Talk to your doctor to see if this trial is right for you.